Background: Despite the active study of the main pathogenetic mechanisms of benign breast diseases, there is still insufficient information on the lipid peroxidation – antioxidant defense processes activity in women with diffuse mastopathy in the course of menstrual cycle. Such knowledge is necessary for the early detection and prevention of hyperplastic processes and for the development of pathogenically based antioxidant therapy. Research hypothesis: the parameters of the lipid peroxidation – antioxidant defense system in women with diffuse mastopathy vary depending on the period of the menstrual cycle.
Objective: to assess the activity of lipid peroxidation and antioxidant system reactions in women with diffuse mastopathy during the menstrual cycle.
Materials and Methodology: The study included 29 women: 12 healthy ones (mean age 29.6 ± 2.32 years) and 17 women with diffuse mastopathy (mean age 28.8 ± 3.2 years). All women underwent standard collection of anamnesis and clinical examinations. For all women laboratory tests were performed to determine the concentration of lipid peroxidation products and antioxidant defense components. The tests were conducted every 3 days – on days 1–3, 4–6, 7–9, 10–12, 13–15, 16–18, 19–21, 22–24, and on days 25–28. Spectrophotometric and fluorometric methods were used.
Results: Patients with diffuse mastopathy showed an increase in double bonds on days 1–3 (by 1.3 times), days 7–9 (by 1.22 times), 19–21 (by 1.19 times), and on days 22–24 (by 1.53 times); in conjugated dienes – on days 1–3 (by 1.4 times), 4–6 (by 1.2 times), 7–9 (by 1.47 times), 16–18 (by 1.48 times; P = .02), and on days 19–21 (by 1.38 times); in ketodienes and conjugated trienes (during the whole cycle) – on days 1–3 (by 2.64 times), 4–6 (by 1.6 times), 7–9 (by 1.72 times), 10–12 (by 1.39 times), 13–15 (by 1.36 times), 16–18 (by 3.46 times), 19–21 (by 2 times), 22–24 (by 2.54 times), and on days 25–28 (by 3.1 times); in thiobarbituric acid reactants – on days 19–21 (by 1.36 times) and 22–24 (by 1.27 times) compared with the control group. Patients with diffuse mastopathy showed an increase in total antioxidant activity on days 10–12 (by 1.67 times) and 16–18 (by 1.5 times); a decrease in superoxide dismutase activity – on days 16–18 (by 1.09 times) and 25–28 (by 1.25 times), in oxidized glutathione levels – on days 16–18 (by 1.23 times), 22–24 (by 1.14 times), and days 25–28 (by 1.25 times); an increase in reduced glutathione – on days 1–3 (by 1.3 times); a decrease in retinol content – on days 1–3 (by 1.64 times), 4–6 (by 1.2 times; P = .044), 10–12 (by 1.36 times), 19–21 (by 1.24 times) and on days 25–28 (by 1.18 times), and in ascorbate content – on days 7–9 (by 1.11 times) and 10–12 (by 1.16 times).
Conclusion: During our study, we revealed an imbalance of lipid peroxidation – antioxidant defense system. For normalizing the balance in lipid peroxidation – antioxidant defense system, patients with diffuse mastopathy in the luteal phase of the menstrual cycle are recommended to use antioxidant drugs. To prove the general hypothesis further clinical trials are warranted.
Oxidative stress in women with insomnia in different stages of menopause